Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis

Jing Shi, Lotte A. van de Stadt, E. W. Nivine Levarht, Tom W. J. Huizinga, Dörte Hamann, Dirkjan van Schaardenburg, René E. M. Toes, Leendert A. Trouw

Research output: Contribution to journalArticleAcademicpeer-review

177 Citations (Scopus)

Abstract

Objective The presence of anti-citrullinated protein antibodies (ACPA) and IgM-rheumatoid factor (IgM-RF) years before the clinical diagnosis of rheumatoid arthritis (RA) suggests they are possibly involved in the pathogenic process underlying RA. In this study, we analysed whether anti-carbamylated protein (anti-CarP) antibodies, a novel autoantibody system against carbamylated proteins, can also be detected in healthy individuals before they developed RA. Methods Multiple sera from asymptomatic blood donors prior to the onset of their RA symptoms and sera from age-matched and sex-matched controls were tested for the presence of antibodies directed against carbamylated-fetal calf serum (Ca-FCS), carbamylated-fibrinogen (Ca-Fib), cyclic citrullinated-peptide 2 and IgM-RF. Results Anti-Ca-FCS and anti-Ca-Fib antibodies were each present in 27% and 38% of the last serum samples of blood donors prior to the diagnosis of RA. Both anti-Ca-FCS and anti-Ca-Fib antibodies could be detected many years before the onset of RA. Anti-CarP antibodies as well as ACPA are, on average, detected earlier than IgM-RF. Conclusions In addition to ACPA and IgM-RF, also the newly identified anti-CarP antibodies appear many years before the diagnosis of RA
Original languageEnglish
Pages (from-to)780-783
JournalAnnals of the rheumatic diseases
Volume73
Issue number4
DOIs
Publication statusPublished - 2014

Cite this